Sonoma Biotherapeutics
sonomabio.com
Actively hiring
Cell & Gene Therapy
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
8VC, LAV
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 13
Partnership Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle Platform · sonomabio.com
Aug 21, 2025
New executive Sonoma Biotherapeutics Appoints Lisa Taylor Ash, JD, as Chief Legal Officer · sonomabio.com
LAV Similar startupsby what they do, their industry and backers
Redefining Complement Therapies. Complement Therapeutics is a clinical-stage biotechnology company advancing precision therapies for…
Our modular engineering platform allows us to create optimized Tregs phenotypes tailored to address a wide variety of autoimmune…
Immunotherapiesfor fibrotic disease. Neotis is designing therapies that direct the immune system to eliminate cells driving fibrotic…
At Jaguar Gene Therapy, we believe in a world where patients and families won’t have to hear those words. Our mission is to accelerate…
Neurona is developing cell therapies for targeted repair of dysfunctional neural circuits underlying chronic diseases.
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
News
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle Platform
The post Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle Platform appeared first on Sonoma Biotherapeutics.
Read more
Report
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle Platform
SOUTH SAN FRANCISCO, Calif. & SEATTLE, July 13, 2026--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg)
Read more
Report
Cellares and Sonoma Biotherapeutics Collaborate to Automate Manufacturing of SBT-77-7101 Engineered Treg Cell Therapy on the Cell Shuttle Platform - AOL
Read more
Report
Pro access
Upgrade to see all 22 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.